Ressources

cell-background
All our news

ITCC-P4, first company in the world to offer preclinical drug tests for children with cancer

   

triangleDiscover
Publications

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

triangleDiscover
Publications

Targeting genome integrity dysfunctions impedes metastatic potency in non-small-cell lung cancer circulating tumor cellderived eXplants

CTC-derived eXplants (CDX) offer systems for mechanistic investigation of CTC metastatic potency and may provide rationale for biology-driven therapeutics.

triangleDiscover
Publications

STING protects breast cancer cells from intrinsic and genotoxic-induced DNA instability via a non-canonical, cell-autonomous pathway – Oncogene, Oct.8 2021

triangleDiscover
news

ITCC-P4, first company in the world to offer preclinical drug tests for children with cancer

   

triangleDiscover
news

XenTech remains fully operational after 7 weeks of COVID-19 pandemic : update from our COO

In this 7th week of containment and as end of confinement in France is announced for May 11th, I would first of all like to thank you on behalf of our teams for all the messages of support you have sent us since the beginning of the COVID-19 crisis.

triangleDiscover
news

XenTech Covid-19 management

Regarding the current circumstances, we at XenTech want you to know that we are taking the Covid-19 pandemia very seriously. We are closely monitoring the pandemic, following guidance and advice from the World Health Organization (WHO), and the French Government. 

triangleDiscover
publications

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

triangleDiscover
publications

Targeting genome integrity dysfunctions impedes metastatic potency in non-small-cell lung cancer circulating tumor cellderived eXplants

CTC-derived eXplants (CDX) offer systems for mechanistic investigation of CTC metastatic potency and may provide rationale for biology-driven therapeutics.

triangleDiscover
publications

STING protects breast cancer cells from intrinsic and genotoxic-induced DNA instability via a non-canonical, cell-autonomous pathway – Oncogene, Oct.8 2021

triangleDiscover
publications

Paediatric Liver Cancer

A preclinical platform of mouse-transplanted human pediatric liver tumors to evaluate the efficacy of conventional and innovative anticancer therapy

triangleDiscover

01Conferences
& events

04.14.23

XenTech will attend AACR Annual Meeting in Orlando (Apr. 14-19 2023)

Philippe, Olivier and Delphine cordially invite you to stop by our Booth#618 to discuss our solid tumor PDX collection to bring your innovative research projects a step further !

triangleDiscover
03.13.23

XenTech will attend the World ADC London (Mar.- 13-16th)

Philippe and Olivier cordially invite you to stop by our Booth#12 to discuss our long experience in testing ADCs in our solid tumor PDX collection !

triangleDiscover
01.24.23

XenTech will attend the DDR inhibitors Summit 2023 (Boston, Jan. 24-26)

Our Head of R&D Oliver Déas will be delighted to discuss with you as he'll be attending in person.

triangleDiscover
06.20.22

XenTech exhibits at EACR 2022 (Seville, Jun. 20-23 2022)

We'll be exhibiting at EACR in Seville, stop by booth #50 !

triangleDiscover
cell-background

03Discover more

About us

triangleDiscover
xentech-live

Contact us

triangleDiscover